Stay updated on Aptose Biosciences Press Releases
Sign up to get notified when there's something new on the Aptose Biosciences Press Releases page.

Latest updates to the Aptose Biosciences Press Releases page
- Check4 days agoChange DetectedA new press release entry appears for Tuspetinib data at the 2026 EHA Congress, and an older acquisition-related release by Hanmi Pharmaceutical is deleted from the list.SummaryDifference2%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedA new press release entry dated May 29, 2026, titled 'Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical' was added to the press releases list, and the Nov 13, 2025 'Aptose Reports Third Quarter 2025 Results' release was removed.SummaryDifference2%

- Check40 days agoChange DetectedAdded a new press release entry for Aptose Reports First Quarter 2026 Results dated May 13, 2026, and removed the older Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting from the press releases listing.SummaryDifference2%

- Check54 days agoChange DetectedAdded a new press release entry dated Apr 30, 2026 announcing the anticipated timing of the closing of the Plan of Arrangement with Hanmi Pharmaceutical; removed an older release about Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML.SummaryDifference2%

- Check83 days agoChange DetectedAdded a new press release dated Mar 31, 2026: Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights. Deleted the Sep 22, 2025 press release: Aptose and Hanmi Pharmaceutical Extend Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML.SummaryDifference2%

- Check91 days agoChange DetectedAdded a new press release on Mar 23, 2026: 'Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement'. Removed an older press release from Aug 22, 2025: 'Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor'.SummaryDifference2%

Stay in the know with updates to Aptose Biosciences Press Releases
Enter your email address, and we'll notify you when there's something new on the Aptose Biosciences Press Releases page.